Letrozole


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Advanced or locally advanced breast cancer; Adjuvant treatment in early breast cancer In hormone receptor +ve postmenopausal women: 2.5 mg once daily.
Administration
May be taken with or without food.
Contraindications
Premenopausal status. Pregnancy and lactation.
Special Precautions
Patient w/ history of osteoporosis and/or fracture. Severe hepatic impairment (Child-Pugh score C) or cirrhosis. Patient Counselling This drug may cause somnolence and dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor LH and FSH level prior to therapy. Monitor BP, CBC, thyroid function test, BMD level, serum electrolytes, cholesterol, transaminases, and creatinine periodically.
Adverse Reactions
Significant: Decreased BMD, CNS depression, hypercholesterolaemia. Nervous: Dizziness, insomnia, somnolence, fatigue, headache, hypertension. CV: Peripheral oedema, HTN, MI. GI: Nausea, anorexia, increased appetite, dyspepsia, constipation, abdominal pain, diarrhoea, vomiting. Resp: Dyspnoea, cough. Hepatic: Increased liver enzymes. Genitourinary: Vag bleeding. Endocrine: Hot flushes, wt gain. Haematologic: Thrombocytopenia. Musculoskeletal: Osteoporosis, bone fracture, arthralgia, myalgia. Dermatologic: Sweating, alopecia; erythematous, psoriaform, maculopapular or vesicular rash, dry skin.
Drug Interactions
Tamoxifen, anti-oestrogen agent, oestrogen-containing drugs may diminish the pharmacological action of letrozole. Decreased plasma concentration w/ strong CYP3A4 inducers (e.g. rifampicin).
ATC Classification
L02BG04 - letrozole ; Belongs to the class of enzyme inhibitors. Used in endocrine therapy.
Disclaimer: This information is independently developed by CIMS based on letrozole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in